Supplemental material, sj-xlsx-2-vet-10.1177_03009858231162209 for Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signature by Luca Licenziato, Lucia Minol
Over 80% of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP achieve complete remission with variable 5-year overall survival (OS) rates of 60 to 70% depending on the preexistin